Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammation
Fierce Biotech
JPM26: Gilead eyes new deals from a 'position of strength'
Across virology, oncology and inflammation, Gilead has "the luxury of being selective" in the external assets it considers adding to its pipeline.
Darren Incorvaia
Jan 14, 2026 3:30am
InflaRx charts layoffs, cost cuts to lift lead asset's prospects
Jan 8, 2026 11:03am
New treatments needed in chronic hand eczema: GlobalData
Dec 19, 2024 3:35pm
Apellis homes in on possible source of rare Syfovre side effect
Aug 23, 2023 9:28am
Apellis bolsters case for Syfovre amid second-quarter earnings
Jul 31, 2023 9:58am
Experts report eye inflammation cases linked to Apellis' Syfovre
Jul 17, 2023 5:30pm
